BeiGene | Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

⟵ Back to Search Results

Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

Beigene Study ID

BGB-HNSCC-201

ClinicalTrials.gov ID

NCT05909904

China Drug Trials ID

CTR20232123

Sex: All

Age: 18 Years / N/A

No Study Documents

Sex: All

Age: 18 Years / N/A

No Study Documents